Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices

Fig. 2

Murine PCLS. a Concentration-response curve of imatinib in naïve PAs and PVs: (⃝) PAs (n = 6); (□) PVs (n = 7). b Concentration-response curve of ET-1 in naïve murine pulmonary vessels: () PA (n = 7); (■) PV (n = 6). c The contractile effect of 100 nM ET-1 in PAs and PVs: () PA (n = 4); (■) PV (n = 5). d Effect of increasing concentrations of imatinib in pre-constricted PAs: (⃝) 100 nM ET-1 (n = 8); () 100 nM ET-1 / imatinib (n = 10). e Effect of increasing concentrations of imatinib in pre-constricted PVs: (□) 100 nM ET-1 (n = 8); (■) 100 nM ET-1 / imatinib (n = 10). f Effect of increasing concentrations of imatinib in pre-constricted PVs: (□) 1 μM ET-1 (n = 7); (■) 1 μM ET-1 / imatinib (n = 9). g Concentration-response of PDGF-BB in murine PAs and PVs: () PA (n = 10); (■) PV (n = 7). h The contractile effect of PDGF-BB in PAs: () 100 nM PDGF-BB (n = 12); () 1 μM imatinib / 100 nM PDGF-BB (n = 7); () 100 nM amlodipine / 100 nM PDGF-BB (n = 5). b, d EC50 values were calculated using the standard 4-paramter logistic non-linear regression model. c, h Statistics was performed by a linear mixed model analysis (LMM). f, g Statistics was performed by the Mann-Whitney U test. P < 0.05 are considered as significant: * p < 0.05,** p < 0.01 and *** p < 0.001

Back to article page